Clinical trial
A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With…
NCT00251511 · Veeda Oncology, Other · Terminated
Key facts
| NCT number | NCT00251511 |
|---|---|
| Title | A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome |
| Official title | A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome |
| Lead sponsor | Veeda Oncology, Other |
| Collaborators | Cephalon Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome |
| Intervention type | Drug |
| Interventions | Arsenic Trioxide |
| Enrollment | 60 |
| Start date | Aug 1, 2004 |
| Primary completion | Jan 1, 2006 |
| Completion | May 1, 2007 |
| First posted | Nov 10, 2005 |
| Last update posted | May 11, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: